-+ 0.00%
-+ 0.00%
-+ 0.00%

ARCUTIS BEGINS ENROLLING PHASE 3 STUDY EVALUATING ZORYVE® (ROFLUMILAST) CREAM 0.3% IN MODERATE TO SEVERE ATOPIC DERMATITIS

Reuters·11/05/2026 13:00:06

Please log in to view news